Additionally, the integrin/FAK-dependent signaling appears to act in synergy with RTKs (e.g., EGFR, ErbB2, and c-Met) to impact NSCLC malignancy and susceptibility to current therapies (Yoshimasu et al., 2004; Caccavari et al., 2010; Lawson et al., 2010). Here, PTK2 is linked to non-small cell lung carcinoma.